U.S. Markets close in 1 hr 51 mins

Neuralstem, Inc. (CUR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.17+0.00 (+0.43%)
As of 2:06PM EDT. Market open.
People also watch
ATHXCYTXPSTIOPXAOSIR
  • j
    jim b
    jim b
    Someone might want to update that one year target price of $26. Just saying.
  • D
    Dump
    Dump
    $CUR is a buy today $1.17. Good Luck!
  • A
    Anna
    Anna

    Things seem to be getting overextended for CUR. Im not sure about you guys but https://activepennystocks1.blogspot.com has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.

    Penny Stock
    activepennystocks1.blogspot.com
  • B
    BlockbusterPicks
    BlockbusterPicks

    MEGA OPP on this one ...
    SLNO (MC $25 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market /NO Debt = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $25 Million
    Cash: $8 Million
    Price $0.51

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • H
    HiTechInvesting
    HiTechInvesting
    Nice $CUR OTIC and HTBX all oversold biotech plays
  • P
    Pit
    Pit
    Wake up long!
    Imagejust-usmadd
  • K
    Kaylee
    Kaylee
    Anyone ever try out the-stock*dork ? I saw a post about them on the CUR board and ever since I have been hooked. .
  • M
    Maria
    Maria
    Do you think this thing is done selling? Showing us a buy signal now on CUR? if you guys have questions you should ask awe-som*sto-cks. They often respond to my emails which is helpful.
  • P
    Paul
    Paul
    CUR to change their stock symbol to FAIL! They feel this better reflects the path they are following!
  • J
    Jon
    Jon
    Any idea what caused the spike in price and volume around 10 AM? Seems to be too late to be related to the article about the FDA developing guidelines about stem cell treatments and shutting down unauthorized clinics.
  • J
    Jason
    Jason

    http://www.freepatentsonline.com/9744194.pdf for everyone looking for the patent from yesterday

    Methods of treating ischemic spasticity
    Complete Patent Searching Database and Patent Data Analytics Services.
    www.freepatentsonline.com
  • J
    James
    James
    Too much SPAM!
  • P
    Paul
    Paul
    I can't wait to see this company go bankrupt!!! I'll be sooooo happy!!! Total scam and cost a lot of people a lot of money! Good riddance to them!!!
  • F
    Faith
    Faith
    If we are to go off the RSI then you could argue that a pull back next day or so could occur on CUR before rallying up. Yo you should really check out awe-some_sto-cks, they seem on point with their stocks.
  • J
    JujuP
    JujuP
    WOW !!!! CUR up to .09 cents on a pre-split basis. Great job Daly !!!!! Top notch ! TOP NOTCH !!!!

    lol
  • d
    dog
    dog
    NIce to see stock's base slowly rising.
  • R
    Rookie Investor
    Rookie Investor
    I am starting to see this stock on a lot of watch lists but have not figured out why yet. Techs/charts alone not enough for me. Researching fundamentals.
  • D
    Devin
    Devin
    thx to Steve (I think?) for AVEO recommendation. did DD, got in at 2.35 dip, riding it to 4 in short order. that's what a good biotech looks like. anybody else in this?
  • k
    kurbskie
    kurbskie
    "Human neural stem cell transplantation into the corpus callosum of Alzheimer's mice"
    wiley online
    17 august 2017

    Dr. Eva Feldman is still working with hk-532
  • d
    dog
    dog
    It's looking like it wants to make a big move up. Willl it be a news catalyst, or a move on its own right??